By Andrew Karpan ( October 3, 2022, 8:52 PM EDT) -- The U.S. Supreme Court on Monday refused to wade into nine patent cases, turning down Biogen's efforts to block its billion-dollar multiple sclerosis drug Tecfidera from facing market competition and a bid from a prolific patent filer alleging that the U.S. Patent and Trademark Office had developed a "no patents" rule specifically for him, among other matters....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.